Drug repurposing in pancreatic ductal adenocarcinoma


Illustration: Ksenija Pantelić

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal types of cancer with a five-year survival rate of less than 5%. The goal of the REPANCAN project is to decrease the high cost and long development times of new drugs for pancreatic cancer using the drug repurposing concept for a class of imidazoline receptor agonists. Objectives of the project are to establish 1) a novel prognostic marker, 2) novel drug target and 3) a ground for repurposing of low-cost drugs in pancreatic cancer. The REPANCAN project brings together a multidisciplinary team of scientists from the Institute of Oncology and Radiology of Serbia (IORS) and the Clinic for Digestive Surgery of the Clinical Center of Serbia under the leadership of Dr Jelena Grahovac.

REPANCAN project is generously funded by the Science Fund of the Republic of Serbia, PROMIS No 6056979, and the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 891135

Scroll to Top